In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based DrugsRAJASEKARAN, R; SETHUMADHAVAN, Rao.Applied biochemistry and biotechnology. 2010, Vol 160, Num 6, pp 1723-1733, issn 0273-2289, 11 p.Article

Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging : Mass Spectrometry - One of the pillars of ProteomicsMARKO-VARGA, György; FEHNIGER, Thomas E; REZELI, Melinda et al.Journal of proteomics (Print). 2011, Vol 74, Num 7, pp 982-992, issn 1874-3919, 11 p.Article

Syndrome mains-pieds : nouvel effet secondaire de l'erlotinib = Hand-foot syndrome : A new side effect of erlotinibROUXEL, A.-M; ROGUEDAS, A.-M; DESCOURT, R et al.Annales de dermatologie et de vénéréologie. 2008, Vol 135, Num 11, pp 762-764, issn 0151-9638, 3 p.Article

2009: l'année de la maintenance en première ligne ? = 2009: the year of first-line maintenance?PEROL, M.Revue de pneumologie clinique (Paris). 2009, Vol 65, issn 0761-8417, S75-S79, SUP2Conference Paper

Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skinACHARYA, Jayati; LYON, Calum; BOTTOMLEY, David M et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 1, pp 154-157, issn 0190-9622, 4 p.Article

Erupción acneiforme inducida por erlotinib que respeta el área de piel previamente irradiada = Eriotinib-induced acneiform rash not affecting previously irradiated skinEGUREN, C; DOMINGUEZ-FERNANDEZ, I; SANTIAGO-SANCHEZ-MATEOS, D. I et al.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 2, pp 186-187, issn 0001-7310, 2 p.Article

Higher severity grade of erlotinib-induced rash is associated with lower skin phototypeLUU, M; BOONE, S. L; PATEL, J et al.Clinical and experimental dermatology (Print). 2011, Vol 36, Num 7, pp 733-738, issn 0307-6938, 6 p.Article

Folliculitis decalvans associated with erlotinibHOEKZEMA, R; DRILLENBURG, P.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 8, pp 916-918, issn 0307-6938, 3 p.Article

Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation fieldCHIU, H. Y; CHENG, Y. P; JEE, S. H et al.Clinical and experimental dermatology (Print). 2012, Vol 37, Num 8, pp 922-924, issn 0307-6938, 3 p.Article

Density of Demodex folliculorum in Patients Receiving Epidermal Growth Factor Receptor InhibitorsGERBER, Peter A; KUKOVA, Gabriela; BUHREN, Bettina A et al.Dermatology (Basel). 2011, Vol 222, Num 2, pp 144-147, issn 1018-8665, 4 p.Article

Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinomaSUNG HOON SIM; HAN, Sae-Won; DAE SEOG HEO et al.Lung cancer. 2009, Vol 65, Num 2, pp 204-207, issn 0169-5002, 4 p.Article

Targeting the epidermal growth factor receptorEL-RAYES, B. F; LORUSSO, P. M.British journal of cancer. 2004, Vol 91, Num 3, pp 418-424, issn 0007-0920, 7 p.Article

Metabolic profiling identifies lung tumor responsiveness to erlotinibFAN, Teresa W.-M; LANE, Andrew N; HIGASHI, Richard M et al.Experimental and molecular pathology. 2009, Vol 87, Num 1, pp 83-86, issn 0014-4800, 4 p.Article

Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinibHEPPER, Donna M; WU, Peggy; ANADKAT, Milan J et al.Journal of the American Academy of Dermatology. 2011, Vol 64, Num 5, pp 996-998, issn 0190-9622, 3 p.Article

Serious Hematologic Complications Following Erlotinib TreatmentSTATHOPOULOS, G. P; TRAFALIS, DiM; ATHANASIOU, A et al.Anticancer research. 2010, Vol 30, Num 3, pp 973-976, issn 0250-7005, 4 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitorsRANSON, M.British journal of cancer. 2004, Vol 90, Num 12, pp 2250-2255, issn 0007-0920, 6 p.Article

Gefitinib ('Iressa', ZDI839) and new epidermal growth factor receptor inhibitorsBLACKLEDGE, G; AVERBUCH, S.British journal of cancer. 2004, Vol 90, Num 3, pp 566-572, issn 0007-0920, 7 p.Article

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—One with a remarkable thoracic response as wellKUIPER, J. L; SMIT, E. F.Lung cancer. 2013, Vol 80, Num 1, pp 102-105, issn 0169-5002, 4 p.Article

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC studyVERGNENEGRE, A; MONNET, I; BONNABAU, H et al.Lung cancer. 2011, Vol 74, Num 2, pp 264-267, issn 0169-5002, 4 p.Article

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3BORGET, I; CADRANEL, J; DANIEL, C et al.The European respiratory journal. 2012, Vol 39, Num 1, pp 172-179, issn 0903-1936, 8 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLCPALLIS, A. G; SYRIGOS, K. N.Lung cancer. 2013, Vol 80, Num 2, pp 120-130, issn 0169-5002, 11 p.Article

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancerJEFFREY PETTY, W; VOELZKE, William R; URBANIC, James J et al.Lung cancer. 2011, Vol 74, Num 3, pp 384-391, issn 0169-5002, 8 p.Article

Generalized Xerotic Dermatitis with Neutrophilic Spongiosis Induced by Erlotinib (Tarceva®)LÜBBE, J; MASOUYE, I; DIETRICH, P.-Y et al.Dermatology (Basel). 2008, Vol 216, Num 3, pp 247-249, issn 1018-8665, 3 p.Article

Significant drug interaction : Phenytoin toxicity due to erlotinibGRENADER, Tal; GIPPS, Maya; SHAVIT, Linda et al.Lung cancer. 2007, Vol 57, Num 3, pp 404-406, issn 0169-5002, 3 p.Article

Comparing the effects of Fe(III) and Cu(II) on the binding affinity of erlotinib to bovine serum albumin using spectroscopic methodsYAN LIU; MINGMAO CHEN; LING SONG et al.Journal of luminescence. 2013, Vol 134, pp 515-523, issn 0022-2313, 9 p.Article